NASDAQ:PLSE - Pulse Biosciences Stock Price, Price Target & More

Get Started

$15.89 +0.43 (+2.78 %)

(As of 05/27/2018 04:00 PM ET)

Previous Close$15.89

Today's Range$15.35 - $15.97

52-Week Range$9.81 - $39.50

Volume48,505 shs

Average Volume148,796 shs

Market Capitalization$268.18 million

P/E RatioN/A

Dividend YieldN/A

Beta2.14

About Pulse Biosciences (NASDAQ:PLSE)

Pulse Biosciences, Inc., a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.

Receive PLSE News and Ratings via Email

Sign-up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:PLSE

CUSIPN/A

Webwww.pulsebiosciences.com

Phone510-906-4600

Debt

Debt-to-Equity RatioN/A

Current Ratio15.41

Quick Ratio15.41

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book Value$2.43 per share

Price / Book6.54

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-25,560,000.00

Net MarginsN/A

Return on Equity-77.03%

Return on Assets-70.27%

Miscellaneous

Employees33

Outstanding Shares16,880,000

Pulse Biosciences (NASDAQ:PLSE) Frequently Asked Questions

What is Pulse Biosciences' stock symbol?

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences (NASDAQ:PLSE) issued its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.51) earnings per share for the quarter. View Pulse Biosciences' Earnings History.

Who are some of Pulse Biosciences' key competitors?

Some companies that are related to Pulse Biosciences include Orthofix (OFIX), Cardiovascular Systems (CSII), K2M Group (KTWO), OraSure Technologies (OSUR), CryoLife (CRY), MiMedx Group (MDXG), Tactile Systems Technology (TCMD), Cerus (CERS), AtriCure (ATRC), AngioDynamics (ANGO), Tandem Diabetes Care (TNDM), SurModics (SRDX), LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK) and Endologix (ELGX).

Who are Pulse Biosciences' key executives?

Pulse Biosciences' management team includes the folowing people:

Mr. Darrin R. Uecker, Pres, CEO & Director (Age 52)
Mr. Brian B. Dow, Principal Accounting Officer, CFO, Sr. VP of Admin & Fin., Treasurer & Sec. (Age 49)
Dr. Richard Nuccitelli Ph.D., Chief Science Officer
Dr. Holly Hartman Ph.D., J.D., VP of Bus. Devel. & Corp. Strategy
Mr. David Danitz, VP of Engineering

When did Pulse Biosciences IPO?

(PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO.

Has Pulse Biosciences been receiving favorable news coverage?

Media headlines about PLSE stock have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pulse Biosciences earned a news impact score of 0.13 on Accern's scale. They also gave press coverage about the company an impact score of 43.79 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Pulse Biosciences' major shareholders?

Pulse Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.89%), Northern Trust Corp (0.55%) and Citadel Advisors LLC (0.19%). Company insiders that own Pulse Biosciences stock include Maky Zanganeh, Mitchell E Levinson, Robert J Greenberg, Robert W Duggan and Thierry B Thaure. View Institutional Ownership Trends for Pulse Biosciences.

Which major investors are selling Pulse Biosciences stock?

PLSE stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, BlackRock Inc. and Northern Trust Corp. View Insider Buying and Selling for Pulse Biosciences.

How do I buy shares of Pulse Biosciences?

Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pulse Biosciences' stock price today?

One share of PLSE stock can currently be purchased for approximately $15.89.

How big of a company is Pulse Biosciences?

Pulse Biosciences has a market capitalization of $268.18 million. Pulse Biosciences employs 33 workers across the globe.

How can I contact Pulse Biosciences?

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-906-4600 or via email at [email protected]

MarketBeat Community Rating for Pulse Biosciences (PLSE)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		114 (Vote Outperform)
Underperform Votes:		112 (Vote Underperform)
Total Votes:		226

MarketBeat's community ratings are surveys of what our community members think about Pulse Biosciences and other stocks. Vote "Outperform" if you believe PLSE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLSE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Pulse Biosciences (NASDAQ:PLSE) Analyst Ratings History

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details

(Data available from 5/27/2016 forward)

Pulse Biosciences (NASDAQ:PLSE) Earnings History and Estimates Chart

Earnings by Quarter for Pulse Biosciences (NASDAQ:PLSE)

Pulse Biosciences (NASDAQ PLSE) Earnings History by Quarter

Date	Quarter	Actual EPS	Release Link	Conference Call
5/8/2018	Q1 2018	($0.51)	View	N/A
3/16/2018	Q4 2017	($0.53)	View	N/A
11/7/2017	Q3 2017	($0.52)	View	N/A
7/27/2017	Q2 2017	($0.43)	View	N/A
5/4/2017	Q2 2017	($0.23)	View	Listen
3/14/2017	Q4 2016	($0.21)	View	N/A
11/14/2016	Q3 2016	($0.21)	View	N/A
8/10/2016	Q2 2016	($0.23)	View	N/A
6/27/2016	Q1 2016	($0.22)	View	N/A

(Earnings results data provided by Zacks Investment Research)

Pulse Biosciences (NASDAQ:PLSE) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Pulse Biosciences (NASDAQ PLSE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 39.30%
Institutional Ownership Percentage: 8.97%

Insider Trading History for Pulse Biosciences (NASDAQ:PLSE)

Pulse Biosciences (NASDAQ PLSE) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/11/2018	Robert W Duggan	Director	Buy	21,353	$23.16	$494,535.48	5,862,422
12/12/2017	Maky Zanganeh	Director	Buy	4,000	$23.07	$92,280.00	332,500
10/19/2017	Robert W Duggan	Major Shareholder	Buy	22,901	$22.79	$521,913.79	5,820,513
9/24/2017	Robert W Duggan	Major Shareholder	Buy	2,000,000	$15.02	$30,040,000.00	5,797,612
9/18/2017	Maky Zanganeh	Director	Buy	29,775	$13.36	$397,794.00	315,725
9/18/2017	Robert W Duggan	Major Shareholder	Buy	409,918	$14.36	$5,886,422.48	3,437,994
9/14/2017	Mitchell E Levinson	Director	Buy	3,835	$12.30	$47,170.50
8/3/2017	Maky Zanganeh	Director	Buy	28,790	$23.96	$689,808.40	287,225
8/3/2017	Robert W Duggan	Major Shareholder	Buy	277,450	$23.14	$6,420,193.00	3,153,234
8/2/2017	Maky Zanganeh	Director	Buy	8,290	$25.15	$208,493.50	287,225
5/23/2017	Robert W Duggan	Major Shareholder	Buy	83,928	$26.86	$2,254,306.08	3,054,244
5/22/2017	Robert W Duggan	Major Shareholder	Buy	34,728	$26.25	$911,610.00	3,054,244
5/12/2017	Thierry B Thaure	Director	Sell	10,000	$24.40	$244,000.00	10,000
5/11/2017	Robert W Duggan	Major Shareholder	Buy	43,389	$21.04	$912,904.56	2,984,227
5/10/2017	Robert J Greenberg	Director	Sell	25,000	$21.12	$528,000.00	25,000
5/8/2017	Thierry B Thaure	Director	Sell	15,000	$22.49	$337,350.00	15,000
4/28/2017	Robert W Duggan	Major Shareholder	Buy	84,348	$23.88	$2,014,230.24	2,958,579
4/27/2017	Robert W Duggan	Major Shareholder	Buy	35,387	$24.79	$877,243.73	2,923,379
4/19/2017	Robert W Duggan	Major Shareholder	Buy	150,123	$23.77	$3,568,423.71	2,601,850
4/18/2017	Robert W Duggan	Major Shareholder	Buy	61,819	$25.49	$1,575,766.31	2,601,850
4/17/2017	Robert W Duggan	Major Shareholder	Buy	107,300	$24.81	$2,662,113.00	2,601,850
4/10/2017	Robert W. Duggan	Major Shareholder	Buy	191,464	$19.75	$3,781,414.00
3/20/2017	Maky Zanganeh	Director	Buy	18,240	$23.34	$425,721.60	263,935
3/18/2017	Robert W Duggan	Major Shareholder	Buy	205,127	$23.56	$4,832,792.12	2,174,479

(Data available from 1/1/2013 forward)

Pulse Biosciences (NASDAQ PLSE) News Headlines

Source:

Date	Headline
	Pulse Biosciences (PLSE) Director Buys $494,535.48 in Stock www.americanbankingnews.com - May 15 at 10:12 PM
	Pulse Biosciences (PLSE) Lowered to "Sell" at BidaskClub www.americanbankingnews.com - May 15 at 12:36 AM
	Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 12 at 9:58 AM
	Form S-3 Pulse Biosciences, Inc. www.streetinsider.com - May 11 at 10:10 AM
	BRIEF-Pulse Biosciences - Files Prospectus Related To Sale Of Up To 2.1 Mln Shares Of Common Stock www.reuters.com - May 11 at 10:10 AM
	Pulse Biosciences (PLSE) Announces Quarterly Earnings Results www.americanbankingnews.com - May 10 at 5:11 PM
	Pulse Biosciences (PLSE) & Motus GI (MOTS) Critical Survey www.americanbankingnews.com - May 8 at 3:04 AM
	Pulse Biosciences (PLSE) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - May 5 at 6:37 AM
	Pulse Biosciences to Report First Quarter 2018 Financial Results and Operational Highlights finance.yahoo.com - April 30 at 4:32 PM
	Pulse Biosciences (PLSE) Rating Lowered to Sell at BidaskClub www.americanbankingnews.com - April 25 at 12:24 AM
	Pulse Biosciences: Failed FDA Clearance, New SEC Investigation, And An Uncertain Path Forward seekingalpha.com - April 24 at 4:47 PM
	Pulse Biosciences (PLSE) Upgraded at BidaskClub www.americanbankingnews.com - April 17 at 9:57 AM
	Pulse Biosciences, Inc. (PLSE) Announces Results from Its First Study Evaluating Clinical Target at Major Scientific Meeting www.streetinsider.com - April 14 at 4:19 PM
	US STOCKS ON THE MOVE-JPMorgan, Citigroup, Glaukos, EyeGate Pharma, Michael Kors www.nasdaq.com - April 13 at 4:35 PM
	Why Alaska Air Group, Pulse Biosciences, and BJ's Restaurants Jumped Today www.fool.com - April 13 at 4:35 PM
	BRIEF-Pulse Biosciences Announces Positive Results From Its First Study Evaluating A Clinical Target At Major ... www.reuters.com - April 13 at 4:35 PM
	FDA Nod For Innovus' Kit, PLSE Soars On SK Data, Keep An Eye On ARNA www.nasdaq.com - April 13 at 9:42 AM
	Pulse Bio's NPS technology shows positive effect in eliminating skin growths; shares up 13% premarket seekingalpha.com - April 13 at 9:42 AM
	Pulse Biosciences Inc. (PLSE) Is Up Sharply On Study Results www.nasdaq.com - April 13 at 9:42 AM
	Pulse Biosciences stock soars to lead premarket gainers after positive study results finance.yahoo.com - April 13 at 9:42 AM
	BidaskClub Lowers Pulse Biosciences (PLSE) to Sell www.americanbankingnews.com - March 30 at 5:40 PM
	Pulse Biosciences Grants Equity Incentive Awards to New Employees - Business Wire (press release) www.businesswire.com - March 21 at 4:37 PM
	Pulse Biosciences Grants Equity Incentive Awards to New Employees finance.yahoo.com - March 21 at 4:37 PM
	Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q4 2017 Results ... - Seeking Alpha seekingalpha.com - March 18 at 5:18 PM
	Pulse Biosciences Quarterly Investor Conference Call finance.yahoo.com - March 16 at 5:32 PM
	Is Pulse Biosciences Inc’s (NASDAQ:PLSE) CEO Incentives Align With Yours? finance.yahoo.com - March 16 at 9:38 AM
	Pulse Biosciences (PLSE) and Agilent Technologies (A) Financial Contrast www.americanbankingnews.com - March 8 at 2:07 PM
	Pulse Biosciences (PLSE) Scheduled to Post Quarterly Earnings on Monday www.americanbankingnews.com - March 5 at 2:34 AM
	Pulse Biosciences (PLSE) versus Cynosure (CYNO) Head-To-Head Survey www.americanbankingnews.com - February 24 at 9:12 PM
	BidaskClub Lowers Pulse Biosciences (PLSE) to Strong Sell www.americanbankingnews.com - February 18 at 1:00 PM
	Pulse Biosciences (PLSE) Lifted to "Hold" at ValuEngine www.americanbankingnews.com - February 4 at 5:35 PM
	Financial Comparison: Pulse Biosciences (PLSE) vs. Its Competitors www.americanbankingnews.com - January 31 at 11:16 AM
	Critical Contrast: Pulse Biosciences (PLSE) and The Competition www.americanbankingnews.com - January 31 at 11:16 AM
	Pulse Biosciences Inc (PLSE) Sees Significant Decrease in Short Interest www.americanbankingnews.com - January 30 at 2:44 PM
	Comparing Illumina (ILMN) & Pulse Biosciences (PLSE) www.americanbankingnews.com - January 29 at 5:14 PM
	Pulse Biosciences (PLSE) vs. Reshape Lifesciences (RSLS) Head-To-Head Contrast www.americanbankingnews.com - January 28 at 9:26 AM
	Head to Head Survey: Pulse Biosciences (PLSE) vs. The Competition www.americanbankingnews.com - January 27 at 5:20 PM
	Head to Head Analysis: Pulse Biosciences (PLSE) & Its Rivals www.americanbankingnews.com - January 23 at 9:28 PM
	Reviewing Pulse Biosciences (PLSE) and The Competition www.americanbankingnews.com - January 20 at 7:50 PM
	Pulse Biosciences (PLSE) & Its Competitors Head-To-Head Contrast www.americanbankingnews.com - January 17 at 5:15 PM
	Pulse Biosciences (PLSE) vs. Its Peers Head-To-Head Comparison www.americanbankingnews.com - January 16 at 1:10 PM
	Contrasting Pulse Biosciences (PLSE) and Its Peers www.americanbankingnews.com - January 14 at 5:34 PM
	Critical Comparison: Pulse Biosciences (PLSE) and Its Competitors www.americanbankingnews.com - January 12 at 9:06 AM
	Analyzing Pulse Biosciences (PLSE) & Its Peers www.americanbankingnews.com - January 12 at 8:04 AM
	Pulse Biosciences (PLSE) & The Competition Critical Analysis www.americanbankingnews.com - January 11 at 11:46 AM
	Pulse Biosciences (PLSE) and Luna Innovations (LUNA) Critical Analysis www.americanbankingnews.com - January 10 at 9:46 AM
	Head to Head Review: Pulse Biosciences (PLSE) and The Competition www.americanbankingnews.com - January 9 at 11:04 AM
	Pulse Biosciences (PLSE) and Its Peers Head to Head Analysis www.americanbankingnews.com - January 8 at 3:30 AM
	Analyzing Pulse Biosciences (PLSE) & Its Competitors www.americanbankingnews.com - January 3 at 11:30 PM
	Pulse Biosciences (PLSE) Upgraded to Hold at ValuEngine www.americanbankingnews.com - January 1 at 12:52 PM

Pulse Biosciences (NASDAQ:PLSE) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Pulse Biosciences (NASDAQ:PLSE) Income Statement, Balance Sheet and Cash Flow Statement

Pulse Biosciences (NASDAQ PLSE) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff